WO2002058718A3 - Methodes et compositions permettant de stimuler l'angiogenese - Google Patents

Methodes et compositions permettant de stimuler l'angiogenese Download PDF

Info

Publication number
WO2002058718A3
WO2002058718A3 PCT/US2002/001666 US0201666W WO02058718A3 WO 2002058718 A3 WO2002058718 A3 WO 2002058718A3 US 0201666 W US0201666 W US 0201666W WO 02058718 A3 WO02058718 A3 WO 02058718A3
Authority
WO
WIPO (PCT)
Prior art keywords
promoting angiogenesis
compositions containing
containing pdgf
pdgf
factors
Prior art date
Application number
PCT/US2002/001666
Other languages
English (en)
Other versions
WO2002058718A2 (fr
Inventor
Robert Pawliuk
Philippe Leboulch
Original Assignee
Genetix Pharmaceuticals Inc
Robert Pawliuk
Philippe Leboulch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetix Pharmaceuticals Inc, Robert Pawliuk, Philippe Leboulch filed Critical Genetix Pharmaceuticals Inc
Priority to AU2002247007A priority Critical patent/AU2002247007B2/en
Priority to JP2002559052A priority patent/JP4434584B2/ja
Priority to CA002436076A priority patent/CA2436076A1/fr
Priority to EP02714757A priority patent/EP1355659A2/fr
Priority to US10/198,917 priority patent/US20030139333A1/en
Publication of WO2002058718A2 publication Critical patent/WO2002058718A2/fr
Publication of WO2002058718A3 publication Critical patent/WO2002058718A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des méthodes permettant de stimuler l'angiogenèse par l'administration de facteurs angiogéniques. Ces facteurs peuvent être administrés sous forme de gradient dans une zone de tissu localisée afin de diriger la croissance vasculaire.
PCT/US2002/001666 2001-01-26 2002-01-18 Methodes et compositions permettant de stimuler l'angiogenese WO2002058718A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002247007A AU2002247007B2 (en) 2001-01-26 2002-01-18 Use of compositions containing PDGF-BB for promoting angiogenesis
JP2002559052A JP4434584B2 (ja) 2001-01-26 2002-01-18 血管新生を促進する方法及び組成物
CA002436076A CA2436076A1 (fr) 2001-01-26 2002-01-18 Methodes et compositions permettant de stimuler l'angiogenese
EP02714757A EP1355659A2 (fr) 2001-01-26 2002-01-18 Methodes et compositions permettant de stimuler l'angiogenese
US10/198,917 US20030139333A1 (en) 2002-01-18 2002-07-19 Methods and compositions for promoting angiogenesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26445701P 2001-01-26 2001-01-26
US60/264,457 2001-01-26

Publications (2)

Publication Number Publication Date
WO2002058718A2 WO2002058718A2 (fr) 2002-08-01
WO2002058718A3 true WO2002058718A3 (fr) 2003-04-17

Family

ID=23006154

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/001666 WO2002058718A2 (fr) 2001-01-26 2002-01-18 Methodes et compositions permettant de stimuler l'angiogenese

Country Status (5)

Country Link
EP (1) EP1355659A2 (fr)
JP (1) JP4434584B2 (fr)
AU (1) AU2002247007B2 (fr)
CA (1) CA2436076A1 (fr)
WO (1) WO2002058718A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
JP2005168654A (ja) * 2003-12-09 2005-06-30 Kissei Pharmaceut Co Ltd 増殖因子結合低分子ヘパリン修飾体
FR2891149B1 (fr) * 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
EP1948210A4 (fr) 2005-11-08 2010-07-14 Found Biomedical Res & Innov Methode de traitement d'une maladie cardiaque ischemique
FR2914191A1 (fr) * 2007-03-29 2008-10-03 Proteins & Peptides Man Composition angiogenique.
CN102196822A (zh) 2008-09-26 2011-09-21 阿道恰公司 由多糖和hbp构成的复合物
WO2010078624A1 (fr) * 2009-01-07 2010-07-15 Vegenics Limited Matériaux et méthodes pour le traitement de l’hypertension
GB201504665D0 (en) * 2015-03-19 2015-05-06 Cell Therapy Ltd Composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000060A1 (fr) * 1988-06-30 1990-01-11 Collagen Corporation Matrices collagenes de cicatrisation de blessures et leur procede de production
WO1991016009A1 (fr) * 1990-04-17 1991-10-31 Curative Technologies, Inc. Procede utilise pour recouvrir des surfaces de protheses avec des cellules de mammiferes
US5128321A (en) * 1986-08-13 1992-07-07 Zymogenetics, Inc. PDGF analogs and methods of use
WO1994025056A2 (fr) * 1993-04-29 1994-11-10 Washington University Utilisation du facteur de croissance derive des plaquettes pour l'amelioration de la circulation collaterale
WO1997012601A2 (fr) * 1995-10-06 1997-04-10 Ethicon, Inc. Formulations de gel contenant des facteurs de croissance
WO2000041732A1 (fr) * 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Compositions hydrogel pour l'administration controlee de vecteurs viraux, et leurs procedes d'utilisation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128321A (en) * 1986-08-13 1992-07-07 Zymogenetics, Inc. PDGF analogs and methods of use
WO1990000060A1 (fr) * 1988-06-30 1990-01-11 Collagen Corporation Matrices collagenes de cicatrisation de blessures et leur procede de production
WO1991016009A1 (fr) * 1990-04-17 1991-10-31 Curative Technologies, Inc. Procede utilise pour recouvrir des surfaces de protheses avec des cellules de mammiferes
WO1994025056A2 (fr) * 1993-04-29 1994-11-10 Washington University Utilisation du facteur de croissance derive des plaquettes pour l'amelioration de la circulation collaterale
WO1997012601A2 (fr) * 1995-10-06 1997-04-10 Ethicon, Inc. Formulations de gel contenant des facteurs de croissance
WO2000041732A1 (fr) * 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Compositions hydrogel pour l'administration controlee de vecteurs viraux, et leurs procedes d'utilisation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
EDELMAN E.R. ET AL.: "Controlled and modulated release of basic fibroblast growth factor.", BIOMATERIALS, vol. 12, no. 7, September 1991 (1991-09-01), pages 619 - 626, XP000226106 *
FRANK K R ET AL: "CONTROLLED RELEASE OF BIOACTIVE GROWTH FACTORS FROM A BIODEGRADABLE DELIVERY SYSTEM", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 11, no. 10, October 1994 (1994-10-01), pages S88,ANBIOTEC2070, XP001068790, ISSN: 0724-8741 *
KAWAI K ET AL: "Accelerated tissue regeneration through incorporation of basic fibroblast growth factor-impregnated gelatin microspheres into artificial dermis - targeted delivery systems", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 21, no. 5, March 2000 (2000-03-01), pages 489 - 499, XP004185546, ISSN: 0142-9612 *
LIECHTY K.W. ET AL.: "Adenoviral-mediated overexpression of platelet-derived growth factor-B corrects ischemic impaired wound healing.", J. INVEST. DERMATOL., vol. 113, no. 3, September 1999 (1999-09-01), pages 375 - 383, XP002211469 *
PARK Y J ET AL: "Controlled release of platelet-derived growth factor-BB from chondroitin sulfate-chitosan sponge for guided bone regeneration", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 67, no. 2-3, July 2000 (2000-07-01), pages 385 - 394, XP004199184, ISSN: 0168-3659 *
PARK Y.J.: "Controlled release of PDGF from porous poly(L-lactide) membranes for guided tissue regeneration.", J. CONTROLLED RELEASE., vol. 51, 1998, pages 201 - 211, XP004113628 *
STEED D L ET AL: "CLINICAL EVALUATION OF RECOMBINANT HUMAN PLATELET-DERIVED GROWTH FACTOR FOR THE TREATMENT OF LOWER EXTREMITY DIABETIC ULCERS", JOURNAL OF VASCULAR SURGERY, C.V. MOSBY CO., ST. LOUIS, MO, US, vol. 1, no. 21, January 1995 (1995-01-01), pages 71 - 81, XP001088899, ISSN: 0741-5214 *
YLÄ-HERTTUALA S. AND MARTIN J.F.: "Cardiovascular gene therapy", LANCET, vol. 355, 15 January 2000 (2000-01-15), pages 213 - 222, XP002211470 *

Also Published As

Publication number Publication date
JP4434584B2 (ja) 2010-03-17
WO2002058718A2 (fr) 2002-08-01
EP1355659A2 (fr) 2003-10-29
JP2005506279A (ja) 2005-03-03
CA2436076A1 (fr) 2002-08-01
AU2002247007B2 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
AU2002335122A1 (en) Adjustable left atrial appendage occlusion device
WO2003022227A3 (fr) Modulation antisens de l'expression du recepteur 1 du facteur de croissance endothelial vasculaire
AU2001283518A1 (en) Method for controlling the pain from injections or minor surgical procedures andapparatus for use therewith
WO2006019728A3 (fr) Dispositif et procede pour traiter un vaisseau sanguin
GB2370506B (en) Catheter tip
AU2003267203A8 (en) Method for administering thermotherapy to prevent the growth of tumors
AU2002318197A1 (en) Catheter tip
AU2956101A (en) Improved lumen design for catheter
AU2001278852A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2006014673A3 (fr) Conjugues insuline-oligomere, preparations et utilisations de ceux-ci
EP1214057A4 (fr) Composition de revetement vasculaire
AU1200501A (en) Drug delivery catheters that attach to tissue and methods for their use
IL165022A0 (en) Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
AU8707601A (en) Heart support to prevent ventricular remodeling
ZA200108082B (en) Pharmaceutical compositions comprising dipeptidy peptidase IV inhibitors for the promotion of growth.
AU2002248304A1 (en) Vascular tissue composition
AU2002219849A1 (en) Prosthetic heart valve with increased lumen
AU2002216897A1 (en) Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect
HK1042247A1 (en) Use of benzazepine-n ethanoic acid derivatives forpreparation of medicament for treating pulmonary hypertension.
WO2002058718A3 (fr) Methodes et compositions permettant de stimuler l'angiogenese
WO2003023004A3 (fr) Modulation de l'expression du recepteur 3 du facteur de croissance fibroblastique
WO2001000566A3 (fr) Acides phenoxyacetiques substitues
AU2001275707A1 (en) Use of panaxatriol for stimulation angiogenesis
AU7315701A (en) Optically pure(-) clethodim, compositions and methods for controlling plant growth comprising the same
AU1878201A (en) Composition for the treatment of damaged tissue

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10198917

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002714757

Country of ref document: EP

Ref document number: 2436076

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002559052

Country of ref document: JP

Ref document number: 2002247007

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002714757

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642